Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinba's Total Profit
Date:10/7/2008

XI'AN, China, Oct. 7 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB; the "Company"), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in Xi'an, China, is pleased to announce the signing of a formal exclusive management agreement with Xi'an Qinba Xintong Medical Ltd ("Qinba"). On Sept 5, 2008 the company announced a Letter of Intent to enter into a contractual arrangement with Qinba.

Under the terms of this arrangement, Huifeng will assume operational control of Qinba and will receive a management fee equal to 70% of Qinba's total profit.

Mr. Jing'An Wang, CEO and founder stated "This is Huifeng's first step toward our vertical integration strategy, and we intend to transform the company from a producer of raw materials for the Traditional Chinese Medicine industry to a full-scale pharmaceutical company supplying end products to consumers worldwide".

"As a franchiser of finished medical devices, Qinba will give Huifeng immediate access to pharmacy and medicine buyers," said CEO Wang. "With this management agreement, Huifeng has taken the first step toward positioning itself for synergistic growth beyond its core revenue base."

"Now that we have completed the first vertical integrations, we have proven our ability to attract accretive deals within the People's Republic of China," continued Mr. Wang. "Moving forward, we hope to close on several larger strategic partnerships."

Huifeng issued an 8K filing pertaining to this agreement on September 29. To read the text of the filing, go to http://www.premierstocks.tv/info/hfgb_8k.pdf

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties in Xi'an China. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

This press release may contain forward-looking statements. These statements are based on the current expectations or beliefs of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements, including but not limited to the fluctuation of prices of raw materials, the market demand for our products, changes in governmental regulations and/or economic policies and our ability to penetrate new markets.

For more information, please contact:

Dan Carlson

Primary Capital LLC

Email: DCarlson@PrimaryLLC.com

Kelly Black

CEO Premier Media Services, Inc.

Tel: +1-480-649-8224

Email: kblack@premiermediaserice.com


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
2. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
3. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
4. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
5. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
6. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
7. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
8. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
9. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
10. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
11. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... and Azusa, CA (PRWEB) , ... December 07, ... ... of distributed wastewater treatment and resource recovery solutions for industrial facilities, today announced ... , will be the first to use Cambrian’s novel water-energy purchase agreement (WEPA). ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... access program for SmartBiome -- a novel metagenomic deep-sequencing research platform. SmartBiome ... and detection of hundreds of different genes. The selective early access program ...
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... for the fourth quarter and fiscal year ended September 30, 2016. ... , , ... -based life sciences and diagnostics company that develops and commercializes proprietary ... Highlights Achieved revenues of $1.4 million more than ...
(Date:12/6/2016)... ... 06, 2016 , ... Discovering new clues to natural treatments that could allow ... in our brains. And searching for keys to our immune systems by studying parasite-resistant ... the 2017 Edith and Peter O’Donnell Awards by The Academy of ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/28/2016)... , Nov. 28, 2016 ... rate of 16.79%" The biometric system market is ... further in the near future. The biometric system market ... in 2022, at a CAGR of 16.79% between 2016 ... integration of biometric technology in smartphones, rising use of ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):